298 related articles for article (PubMed ID: 31945808)
1. The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer.
Gruhl JD; Garrido-Laguna I; Francis SR; Affolter K; Tao R; Lloyd S
Cancer Med; 2020 Mar; 9(5):1703-1711. PubMed ID: 31945808
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
3. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
4. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
5. Survival and prognostic factors in patients with pancreatic squamous cell carcinoma.
Tella SH; Kommalapati A; Yadav S; Bergquist JR; Truty MJ; Durgin L; Ma WW; Cleary SP; McWilliams RR; Mahipal A
Eur J Surg Oncol; 2019 Sep; 45(9):1700-1705. PubMed ID: 31118133
[TBL] [Abstract][Full Text] [Related]
6. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
7. A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy.
Kubo K; Wadasaki K; Komichi D; Sasaki T; Yamada H; Matsugu Y; Itamoto T; Doi M; Shinozaki K
PLoS One; 2019; 14(12):e0227305. PubMed ID: 31887205
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
[TBL] [Abstract][Full Text] [Related]
10. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study.
Han D; Gao F; Liu JL; Wang H; Fu Q; Yang GW
BMC Cancer; 2021 May; 21(1):560. PubMed ID: 34001035
[TBL] [Abstract][Full Text] [Related]
11. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
12. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
14. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
15. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
[TBL] [Abstract][Full Text] [Related]
16. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
[TBL] [Abstract][Full Text] [Related]
17. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
[TBL] [Abstract][Full Text] [Related]
18. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
[TBL] [Abstract][Full Text] [Related]
19. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
20. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]